de Vere White Ralph, Lara Primo N
Urol Oncol. 2014 May;32(4):380-2. doi: 10.1016/j.urolonc.2013.09.010.
The rapid evolution of palliative therapeutic choices in the last few years for patients with advanced castration-resistant prostate cancer (CRPC) has resulted in a dilemma currently troubling a few other epithelial malignancies: which systemic agent to choose and at what time? In addition, which specialty specifically directs the delivery of such care--Urology or Medical Oncology--has not been clearly established.
Recognizing the lack of consensus, we propose a framework for Urology and Medical Oncology interactions that is founded on models that have succeeded in the past.
This approach aims to focus the care on the patient with CRPC rather than on his physicians and promises to improve patient outcomes in this disease state.
在过去几年中，晚期去势抵抗性前列腺癌（CRPC）患者姑息治疗选择的迅速演变，导致了目前困扰其他一些上皮性恶性肿瘤的困境：选择哪种全身治疗药物以及何时选择？此外，尚未明确确定具体由哪个专科——泌尿外科还是医学肿瘤学——来指导此类治疗的实施。
认识到缺乏共识，我们提出了一个泌尿外科与医学肿瘤学相互作用的框架，该框架基于过去成功的模式。
这种方法旨在将治疗重点放在CRPC患者身上，而不是其医生身上，并有望改善这种疾病状态下的患者预后。
